Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharmaceutical company MannKind
So what: MannKind is approaching a decision date for its inhaled insulin product, and investors are making bets on what the result will be. Option activity was up today and volume was nearly seven times average, and I expect more volatility through the end of the year.
Now what: If Afrezza is the drug MannKind thinks it can be, this stock will shoot higher to end the year, and investors who own the stock will make a killing on the stock. But the Food and Drug Administration has handed down some surprising defeats in recent months, and this isn't a slam-dunk case after Pfizer
Interested in more info on MannKind? Add it to your watchlist.